Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI Xyotax PIONEER Study Closes In Favor Of Normal Estrogen Level Protocol

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Cell Therapeutics will submit a new Xyotax (paclitaxel poliglumex) trial protocol to FDA by the end of the month after closing its Phase III PIONEER gender-specific lung cancer trial

You may also be interested in...



CTI further refines Xyotax population in new Phase III

A confirmatory Phase III trial of Cell Therapeutics' polymer-linked paclitaxel Xyotax is recruiting women with advanced non-small cell lung cancer who have premenopausal estrogen levels (>30 pg/mL). The PGT307 trial, designed under a special protocol assessment with FDA, will enroll 450 women with NSCLC performance status 0, 1, or 2, who will be randomized to Xyotax (paclitaxel poliglumex) plus carboplatin or paclitaxel/carboplatin. CTI has been highlighting its plans for a normal estrogen level protocol to support a "gender medicine" NDA (1Pharmaceutical Approvals Monthly, December 2006, p. 11). An earlier gender-specific trial, the PIONEER study, enrolled women with both normal and abnormal estrogen levels, but was terminated late last year due to early cycle deaths in both arms. CTI has been trying to isolate the effect observed in women in its STELLAR pivotal program. The traditional gender-neutral program failed to meet endpoints in the total NSCLC population, but showed a benefit in women...

CTI seeks Xyotax SPA

Seattle-based Cell Therapeutics is requesting a special protocol assessment for its revised Phase III Xyotax (paclitaxel poliglumex) trial, the company announced Jan. 10. CTI closed its Xyotax PIONEER study last month because the drug did not meet its primary endpoint in the overall patient population (1Pharmaceutical Approvals Monthly December 2006, p. 11). The new protocol (PGT306) will examine the investigational oncologic in the population that showed the most benefit - women with normal estrogen levels. CTI expects to enroll 300 patients who are either pre-menopausal or on hormone replacement therapy. Registration data are expected in the second quarter of 2008...

Novartis Signs Xyotax Development Deal With Cell Therapeutics

Novartis has signed a licensing agreement with Cell Therapeutics that could potentially hasten to market the first gender-specific therapy for the treatment of non-small cell lung cancer

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel